Clinical trial
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV…
NCT00054132 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00054132 |
|---|---|
| Title | Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer |
| Official title | A Phase II Study of OSI-774 in Combination With Bevacizumab in Patients With Stage IV Breast Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Breast Carcinoma, Stage IV Breast Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | Bevacizumab, Erlotinib Hydrochloride, Laboratory Biomarker Analysis |
| Enrollment | 38 |
| Start date | Dec 1, 2002 |
| Primary completion | Apr 1, 2015 |
| Completion | Apr 1, 2015 |
| First posted | Feb 6, 2003 |
| Last update posted | Jul 24, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: